Post-Conference Perspectives: ctDNA for MRD in Lung Cancer

Mark G. Kris, MD, FASCO provides insight on monitoring patients with NSCLC and discusses the developing role of ctDNA.

EP. 1: Current Treatment Options for Patients with NSCLC

July 7th 2022

Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.

EP. 2: Strategies for Monitoring Patients with NSCLC

July 7th 2022

Practical advice on monitoring options for patients with NSCLC treated with definitive radiation therapy or surgery.

EP. 3: Two Key Uses for ctDNA in the Clinical Setting

July 7th 2022

Dr. Mark Kris shares insight on ctDNA and its use in detecting MRD in NSCLC.

EP. 4: Review of Recent Data on ctDNA From ASCO 2022

July 7th 2022

A comprehensive review of data presented at ASCO 2022 on ctDNA and MRD detection in NSCLC.

EP. 5: Future Implications of ctDNA in the Management of NSCLC

July 7th 2022

A thoracic oncology expert provides perspective on ctDNA as a tool and its future as part of the NSCLC landscape.